Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

A Phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers.

Spierings EL, Fujii H, Sun B, Walshe T.

J Nutr Sci Vitaminol (Tokyo). 2007 Dec;53(6):536-9.

2.

Oral administration of active hexose correlated compound enhances host resistance to West Nile encephalitis in mice.

Wang S, Welte T, Fang H, Chang GJ, Born WK, O'Brien RL, Sun B, Fujii H, Kosuna K, Wang T.

J Nutr. 2009 Mar;139(3):598-602. doi: 10.3945/jn.108.100297. Epub 2009 Jan 13.

3.

Immunological effect of active hexose correlated compound (AHCC) in healthy volunteers: a double-blind, placebo-controlled trial.

Terakawa N, Matsui Y, Satoi S, Yanagimoto H, Takahashi K, Yamamoto T, Yamao J, Takai S, Kwon AH, Kamiyama Y.

Nutr Cancer. 2008;60(5):643-51. doi: 10.1080/01635580801993280.

PMID:
18791928
4.

Low-dose supplementation with active hexose correlated compound improves the immune response to acute influenza infection in C57BL/6 mice.

Nogusa S, Gerbino J, Ritz BW.

Nutr Res. 2009 Feb;29(2):139-43. doi: 10.1016/j.nutres.2009.01.005.

PMID:
19285605
5.

The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice.

Hirose A, Sato E, Fujii H, Sun B, Nishioka H, Aruoma OI.

Toxicol Appl Pharmacol. 2007 Jul 15;222(2):152-8. Epub 2007 Apr 20.

PMID:
17555784
6.

Effect of Active Hexose Correlated Compound (AHCC) in alcohol-induced liver enzyme elevation.

Kim H, Kim JH, Im JA.

J Nutr Sci Vitaminol (Tokyo). 2014;60(5):348-56. doi: 10.3177/jnsv.60.348.

7.

Alleviating effect of active hexose correlated compound (AHCC) for anticancer drug-induced side effects in non-tumor-bearing mice.

Shigama K, Nakaya A, Wakame K, Nishioka H, Fujii H.

J Exp Ther Oncol. 2009;8(1):43-51.

PMID:
19827270
8.
9.
11.

Assessment of the short-term safety and tolerability of a quantified 80 % ethanol extract from the stem bark of Nauclea pobeguinii (PR 259 CT1) in healthy volunteers: a clinical phase I study.

Mesia K, Cimanga K, Tona L, Mampunza MM, Ntamabyaliro N, Muanda T, Muyembe T, Totté J, Mets T, Pieters L, Vlietinck A.

Planta Med. 2011 Jan;77(2):111-6. doi: 10.1055/s-0030-1250134. Epub 2010 Jul 21.

PMID:
20665369
12.

Randomized, crossover, single-blind, placebo-controlled, human pharmacology clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: multiple-dose pharmacokinetics.

Algorta J, Pena MA, Alvarez A, Maraschiello C, Maruhn D, Windisch M, Mucke HA.

Int J Clin Pharmacol Ther. 2009 Jul;47(7):483-90.

PMID:
19640356
13.

Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.

Lal R, Sukbuntherng J, Luo W, Chen D, Vu A, Tovera J, Cundy KC.

Clin Ther. 2009 Aug;31(8):1776-86. doi: 10.1016/j.clinthera.2009.07.026.

PMID:
19808136
14.

Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.

Lim KS, Kim JR, Choi YJ, Shin KH, Kim KP, Hong JH, Cho JY, Shin HS, Yu KS, Shin SG, Kwon OH, Hwang DM, Kim JA, Jang IJ.

Clin Ther. 2008 Oct;30(10):1817-30. doi: 10.1016/j.clinthera.2008.10.013.

PMID:
19014837
15.

Safety and tolerability of divalproex sodium extended-release in the prophylaxis of migraine headaches: results of an open-label extension trial in adolescents.

Apostol G, Pakalnis A, Laforet GA, Robieson WZ, Olson E, Abi-Saab WM, Saltarelli M.

Headache. 2009 Jan;49(1):36-44. doi: 10.1111/j.1526-4610.2008.01299.x. Epub 2008 Nov 24.

PMID:
19040678
16.

Active hexose correlated compound enhances the immune function of mice in the hindlimb-unloading model of spaceflight conditions.

Aviles H, Belay T, Vance M, Sun B, Sonnenfeld G.

J Appl Physiol (1985). 2004 Oct;97(4):1437-44. Epub 2004 Jun 11.

17.

Phase I trial of pazopanib in patients with advanced cancer.

Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L.

Clin Cancer Res. 2009 Jun 15;15(12):4220-7. doi: 10.1158/1078-0432.CCR-08-2740. Epub 2009 Jun 9.

18.

Correlation of increase in phosphene threshold with reduction of migraine frequency: observation of levetiracetam-treated subjects.

Young W, Shaw J, Bloom M, Gebeline-Myers C.

Headache. 2008 Nov-Dec;48(10):1490-8. doi: 10.1111/j.1526-4610.2008.01292.x.

PMID:
19076647
19.

Active hexose correlated compound modulates LPS-induced hypotension and gut injury in rats.

Doursout MF, Liang Y, Sundaresan A, Wakame K, Fujii H, Takanari J, Devakottai S, Kulkarni A.

Int Immunopharmacol. 2016 Oct;39:280-286. doi: 10.1016/j.intimp.2016.07.023. Epub 2016 Aug 5.

PMID:
27500458
20.

Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.

Martin DE, Galbraith H, Schettler J, Ellis C, Doto J.

Clin Ther. 2008 Oct;30(10):1794-805. doi: 10.1016/j.clinthera.2008.10.006.

PMID:
19014835

Supplemental Content

Support Center